Phase 3 N=1,246 Long Term Safety of Naldemedine
Opioid-induced Constipation
Primary: Number of Participants With Adverse Events — 425; 446; 149; 121 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
Superficial Bladder Cancer
Primary: Incidence of High Grade-Recurrence Free Survival at 360 Days — 7; 7 Participants
N/A N=105 Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy
Diabetes, Gestational · Diabetes, Type 2
Primary: Glycemic Control — 109.5; 107.4 mg/dL
Phase 3 N=709 Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
Kidney Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) — 64.1; 61.5; 58.4 mL/min/1.73m^2
N/A N=30 Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Parkinson's Disease
Primary: Safety: Time to Reach a 4 Point Increase (Worsening) in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score — 15; 14.1 months — p=0.968
Phase 2 N=19 Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Non-Hodgkins Lymphoma
Primary: Rate of PCR Negativity — 14 Participants
Phase 2 N=75 Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
GBS Disease · Streptococcus Agalactiae
Primary: Concentration of Serotype Ia GBS IgG Levels in Infant Serum at Delivery and at Days 42 and 90 of Age — 6.98; 0.24; 6.18; 0.39 µg/mL
N/A N=1,148 Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial)
Adenomatous Polyps
Primary: Mean Number of Adenomas — 0.82; 0.89 adenoma per patient
N/A N=263 Does Capnography Prevent Hypoxemia During Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound?
Hypoxemia
Primary: Number of Participants Experiencing Hypoxemia During Endoscopy — 57; 85 Participants
Phase 2 N=121 Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
Lymphoma. Non-Hodgkin
Primary: Objective Response Rate (ORR) Per Independent Radiologic Review Committee (IRRC) Assessment — 10.3; 2.9 Percent of participants
Phase 2 N=48 Double-Blind Treatment of Major Depressive Disorder With Vilazodone
Major Depressive Disorder
Primary: Montgomery-Åsberg Depression Rating Scale (MADRS) — 13.9; 12.7; 14.5; 13.2 units on a scale — p=0.342
Phase 2 N=244 A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
Opioid-induced Constipation
Primary: Change From Baseline to Last 2 Weeks of the Treatment Period in the Number of Spontaneous Bowel Movements Per Week — 1.42; 1.98; 3.37; 3.64 spontaneous bowel movements…
N/A N=169 Sleep Apnea Intervention for Cardiovascular Disease Reduction
Obstructive Sleep Apnea
Primary: Change From Baseline in 24-hour Blood Pressure at Months 6 and 12 by Pooled Arms — 1.82; 1.06; 0.59; -0.73 mmHg
Phase 3 N=166 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma · Stage III Childhood Hodgkin Lymphoma · Stage IV Childhood Hodgkin Lymphoma
Primary: Second-event-free Survival — 0.91 Probability of survival
Phase 3 N=553 Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
Opioid-induced Constipation
Primary: Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response — 52.5; 33.6 percentage of participants — p=<0.0001